A receptor tyrosine kinase inhibitor, Tyrphostin A9 induces cancer cell death through Drp1 dependent mitochondria fragmentation

Biochemical and Biophysical Research Communications

Volumn 408, Issue 3, 2011, Pages 465-470

  Park, So Jung ^a   Park, Young Jun ^a   Shin, Ji Hyun ^a   Kim, Eun Sung ^a   Hwang, Jung Jin ^b   Jin, Dong Hoon ^b   Kim, Jin Cheon ^b   Cho, Dong Hyung ^a  

^a Kyung Hee University   (South Korea)

^b Asan Medical Center   (South Korea)

Author keywords

Apoptosis; Fission; Mitochondria dynamics; Tyrphositn A9

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE 3; CASPASE INHIBITOR; DYNAMINE RELATED PROTEIN 1; PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; SMALL INTERFERING RNA; TRYPHOSTIN A9; TYRPHOSTIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NEUROBLASTOMA CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

APOPTOSIS; GTP PHOSPHOHYDROLASES; HELA CELLS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; TYRPHOSTINS;

EID: 79955777855     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.04.053     Document Type: Article

References (31)

1. Cho D.H., Nakamura T., Lipton S.A. Mitochondrial dynamics in cell death and neurodegeneration. Cell. Mol. Life Sci. 2010, 67:3435-3447.
2. Frank S., Gaume B., Bergmann-Leitner E.S., Leitner W.W., Robert E.G., Catez F., Smith C.L., Youle R.J. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev. Cell 2001, 1:515-525.
3. Yoon Y., Pitts K.R., McNiven M.A. Mammalian dynamin-like protein DLP1 tubulates membranes. Mol. Biol. Cell 2001, 12:2894-2905.
4. Hoppins S., Nunnari J. The molecular mechanism of mitochondrial fusion. Biochim. Biophys. Acta. 2009, 1793:20-26.
5. Olichon A., Baricault L., Gas N., Guillou E., Valette A., Belenguer P., Lenaers G. Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J. Biol. Chem. 2003, 278:7743-7746.
6. Suen D.F., Norris K.L., Youle R.J. Mitochondrial dynamics and apoptosis. Genes Dev. 2008, 22:1577-1590.
7. Chan D.C. Mitochondria: dynamic organelles in disease, aging, and development. Cell 2006, 125:1241-1252.
8. Grandemange S., Herzig S., Martinou J.C. Mitochondrial dynamics and cancer. Semin. Cancer Biol. 2009, 19:50-56.
9. Cassidy-Stone A., Chipuk J.E., Ingerman E., Song C., Yoo C., Kuwana T., Kurth M.J., Shaw J.T., Hinshaw J.E., Green D.R., Nunnari J. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev. Cell 2008, 14:193-204.
10. Dibb N.J., Dilworth S.M., Mol C.D. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat. Rev. Cancer 2004, 4:718-727.
11. Roskoski R.Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem. Biophys. Res. Commun. 2007, 356:323-328.
12. Hartmann J.T., Haap M., Kopp H.G., Lipp H.P. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr. Drug Metab. 2009, 10:470-481.
13. Jones A.V., Cross N.C. Oncogenic derivatives of platelet-derived growth factor receptors. Cell. Mol. Life Sci. 2004, 61:2912-2923.
14. M Lee J. Inhibition of p53-dependent apoptosis by the KIT tyrosine kinase: regulation of mitochondrial permeability transition and reactive oxygen species generation. Oncogene 1998, 17:1653-1662.
15. Levitzki A., Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annu. Rev. Biochem. 2006, 75:93-109.
16. Jimeno A., Hidalgo M. Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Biochim. Biophys. Acta. 2006, 1766:217-229.
17. Homsi J., Daud A.I. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007, 14:285-294.
18. Ciardiello F., Tortora G G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008, 358:1160-1174.
19. Ishihara N., Nomura M., Jofuku A., Kato H., Suzuki S.O., Masuda K., Otera H., Nakanishi Y., Nonaka I., Goto Y., Taguchi N., Morinaga H., Maeda M., Takayanagi R., Yokota S., Mihara K. Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. Nat. Cell. Biol. 2009, 11:958-966.
20. Grazette L.P., Boecker W., Matsui T., Semigran M., Force T.L., Hajjar R.J., Rosenzweig A. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J. Am. Coll. Cardiol. 2004, 44:2231-2238.
21. Thyberg J. Tyrphostin A9 and wortmannin perturb the Golgi complex and block proliferation of vascular smooth muscle cells. Eur. J. Cell Biol. 1998, 76:33-42.
22. Noonberg S.B., Benz C.C. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 2000, 59:753-767.
23. Deng J., Shimamura T., Perera S., Carlson N.E., Cai D., Shapiro G.I., Wong K.K., Letai A. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res. 2007, 67:11867-11875.
24. Ling Y.H., Lin R., Perez-Soler R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol. Pharmacol. 2008, 74:793-806.
25. Zhang W., Konopleva M., Ruvolo V.R., McQueen T., Evans R.L., Bornmann W.G., McCubrey J., Cortes J., Andreeff M. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008, 22:808-818.
26. Chiou J.F., Tai C.J., Wang Y.H., Liu T.Z., Jen Y.M., Shiau C.Y. Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism. Cancer Biol. Ther. 2009, 8:1904-1913.
27. Chang C.R., Blackstone C. Cyclic AMP-dependent protein kinase phosphorylation of Drp1 regulates its GTPase activity and mitochondrial morphology. J. Biol. Chem. 2007, 282:21583-21587.
28. Cribbs J.T., Strack S. S. Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death. EMBO Rep. 2007, 8:939-944.
29. Taguchi N., Ishihara N., Jofuku A., Oka T., Mihara K. Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. J. Biol. Chem. 2007, 282:11521-11529.
30. Han X.J., Lu Y.F., Li S.A., Kaitsuka T., Sato Y., Tomizawa K., Nairn A.C., Takei K., Matsui H., Matsushita M. CaM kinase I alpha-induced phosphorylation of Drp1 regulates mitochondrial morphology. J. Cell Biol. 2008, 182:573-585.
31. Meuer K., Suppanz I.E., Lingor P., Planchamp V., Göricke B., Fichtner L., Braus G.H., Dietz G.P., Jakobs S., Bähr M., Weishaupt J.H. Cyclin-dependent kinase 5 is an upstream regulator of mitochondrial fission during neuronal apoptosis. Cell Death Differ. 2007, 14:651-661.